Smart-4-Fabry has been conceived and created to obtain a new nanoformulation of GLA, that will improve the efficacy and toleration compared to the actual treatment with non-formulated GLA. The final benefit will be seen as considerable reduction on the Fabry disease treatment cost and a substantial improvement in the life-quality of Fabry disease patients.
Smart-4-Fabry will impact on a major health problem, the existence of new therapies for rare diseases, which constitutes a priority societal challenge as shown in the H2020 Work Programmes.
Smart functional GLA-nanoformulation for Fabry disease”
1rst January 2017